|Mr. Jeffrey W. Renwick||CEO & Director||N/A||N/A||1968|
|Mr. Richard C. Goldstein||CFO & Director||N/A||N/A||1961|
|Mr. Barry M. Polisuk||Chairman & Corp. Sec.||N/A||N/A||1960|
|Mr. Robert Lefler||Director of Operations||N/A||N/A||N/A|
Canntab Therapeutics Limited, a cannabis oral dosage formulation company, researches and develops advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers extended release, flash melt, immediate release, modified release, and bi-layered tablets for treating sleep disorders, posttraumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. The company was formerly known as Telferscot Resources Inc. and changed its name to Canntab Therapeutics Limited in April 2018. Canntab Therapeutics Limited was incorporated in 2010 and is headquartered in Markham, Canada.
Canntab Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.